Sandoz After Three Years Independent: The Biosimilar Thesis Is Working, But the Stock Already Voted

Sandoz has now been independent for nearly three years. The H1 2026 results are the latest data point in the test that matters: does the biosimilar thesis the company built on after the Novartis spinoff actually compound capital, or is it just a narrative the market has been generous with?

The earnings print says the compounder story is still intact. The $478 million antitrust settlement says the legacy overhang is gone. The 24% single-session stock surge says the market is already pricing in a lot of confidence. The job now is to work through what that confidence is buying and whether the underlying metrics still support it.

The headline numbers

H1 net sales of $5.8 billion, up 5% at constant currencies and accelerating to 7% in Q2. This marks Sandoz's 19th consecutive quarter of net sales growth — a run that is uncommon in the generics business, where volume and pricing usually fight each other. Core diluted EPS grew 17% to $1.71. Core EBITDA margin (a cash-earnings proxy before interest, taxes, depreciation, and amortization) expanded 90 basis points to 20.9%, up from 20.0% a year earlier.

The growth engine is clear. Biosimilars — cheaper versions of biologic drugs that require the same manufacturing complexity and regulatory pathway as the originals — grew 20% in H1, accelerating to 22% in Q2. They now represent 33% of net sales, a record share. The old generics book grew only 4% in H1 (a 1% decline at constant currencies) but is no longer the story.

North America did the heavy lifting, up 15% at constant currencies in H1, driven by denosumab biosimilars Wyost and Jubbonti, which landed at 54% and 64% biosimilar market share respectively after launching in mid-2025. That kind of market-share capture on a $4 billion-plus franchise is exactly the kind of evidence the biosimilar thesis needs. Europe was more modest at 3% constant-currency growth, held back by German tender dynamics that are suppressing pricing through 2028.

The peer comparison

The three names the market lumps under "big generics" — Sandoz, Teva, and Viatris — are no longer running the same business model. The label is stale, and the financials confirm it.

Teva reported Q2 revenues of $4.1 billion, down 1% in U.S. dollars. Its generics segment fell 15% in local currency. The growth is in innovative brands — AUSTEDO, AJOVY, and UZEDY together grew 43% and topped $1 billion for the first time. Teva is betting that generics will fund an eventual transition to a biopharma profile. It raised its full-year outlook, but the GAAP operating margin collapsed to 5.6% from 10.9% last year, mostly on acquisition-related R&D from Emalex Biosciences. That is a company in mid-transformation, carrying the weight of both models at once.

Viatris reported Q2 revenues of $3.8 billion, up 3.5% operationally, with adjusted EBITDA of $1.2 billion, up 8%. Solid execution, but the underlying business — a mix of established brands and complex generics — is growing slowly and carrying a gross leverage ratio of 2.9x. It raised guidance, but the engine is volume in established medicines and Greater China growth, not a structural shift in product economics.

Sandoz is the most focused of the three. Biosimilars at 33% of revenue and growing at 20% is a product-mix shift, not a one-off quarter. The company has 36 assets in its biosimilar pipeline, unmatched in breadth, and just secured its first GLP-1 approval in Brazil for semaglutide. The moat is manufacturing scale and in-house development, not licensing. On the comparison set, Sandoz's margin profile (20.9% core EBITDA) and growth trajectory (19th consecutive quarter of sales growth) lead the three. That is the structural argument for the valuation premium the stock now commands.

The settlement overhang is gone

Sandoz resolved all remaining U.S. federal, state, and class-action claims over legacy generic drug pricing. The total settlement is $478.5 million: $400 million paid over seven years starting in 2027 to 43 states and territories, $50 million to states that settled earlier, and $28.5 million to indirect reseller plaintiffs. No admission of wrongdoing. No impact on 2026 guidance.

The financial amount is large but stretched across seven years — roughly $57 million per year — which is about 4.5% of H1 core EBITDA. The bigger payoff is certainty. The litigation had hung over the stock since the spinoff, creating a reference point that kept the valuation suppressed. Removing it doesn't change the earnings stream, but it removes the discount that traders were implicitly applying.

The valuation question is the one that matters now

Shares surged roughly 24% in the session following the release, moving from $56 to $69.44. The stock now trades at roughly 39 times trailing earnings and about 20 times EV/EBITDA. That is rich for a generics-adjacent name — it reflects investor confidence in the biosimilar growth path, but it also means the market has already voted on the thesis.

Full-year 2026 guidance calls for mid-to-high-single-digit sales growth at constant currencies and roughly 100 basis points of core EBITDA margin expansion. Management expects H2 to outpace H1, with Q4 stronger than Q3. The long-term margin target of 24–26% by 2028 is still in place. That path is credible if biosimilar launches stay on track and generics don't deteriorate further.

The headwinds are real, though. Pricing erosion guidance was widened to a mid-single-digit decline for the year, worse than the prior low-to-mid-single-digit expectation. The drivers are U.S. launch dynamics — early entrants face steeper erosion — and Germany's tender rules, which are freezing substitution growth through 2028. Capital expenditure is peaking at roughly $1.1 billion for the year, reflecting biosimilar facility investment in Slovenia. Net debt sits at $3.5 billion with a manageable 1.4x net-debt-to-EBITDA ratio, but the cash burn is deliberate: the company is building the infrastructure for the next wave of launches.

FX is another variable. The 2026 currency assumption has been cut to roughly a 2 percentage-point tailwind on net sales, down from 4 percentage points earlier in the year. That's a headwind of about 2 points on the top line versus the prior plan.

What the factor stack says about positioning

The growth grade is the strongest pillar. Nineteen consecutive quarters of sales growth, with biosimilars expanding both in rate and in revenue share, is durable momentum. The profitability grade is improving — 90 basis points of margin expansion in H1 on a $5.8 billion revenue base shows operating leverage. The safety grade is adequate: investment-grade ratings, 1.4x leverage, borrowing costs below 4%, and $2.3 billion in liquidity. The valuation grade is the warm spot — 39x earnings is not cheap, and it requires the biosimilar execution to continue without a major stumble.

In portfolio terms, Sandoz fits the growth sleeve of a barbell: a focused biosimilar compounder with improving margins, paired against something with yield or balance-sheet ballast on the other side. The trigger that would change that call is a break in the biosimilar launch cadence — specifically, underperformance from Afqlir (aflibercept) in the U.S., a delay in semaglutide in Canada and Brazil, or a wider-than-expected margin miss in H2. Conversely, if Q4 delivers on management's expectation of accelerating momentum, the current multiple stops looking rich and starts looking like it was early.

The market gave Sandoz 24% in a day for a quarter that met expectations and cleared a legal cloud. The biosimilar engine is real, the settlement is behind it, and the peer comparison still favors Sandoz's focused model. But the stock has done the work of convincing investors that the thesis is already won. The next few quarters have to deliver the compounding, not just the conviction.